Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01180790 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT01180790 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT01180790, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.
Interventions
- DRUG Placebo
- DRUG ACH-0141625 (Sovaprevir)
- DRUG Pegylated Interferon alpha-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01180790
The ClinicalTrials.gov registry entry for NCT01180790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01180790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01180790 about?
NCT01180790 is a clinical study titled "Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants". Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.
What is the current status of trial NCT01180790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2010-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01180790?
The interventions under investigation include: Placebo (DRUG), ACH-0141625 (Sovaprevir) (DRUG), Pegylated Interferon alpha-2a (DRUG).
Who is sponsoring clinical trial NCT01180790?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.